If you have a question for our guest, host or DRG please submit it here.
How China has grown through innovation to rival the US market
Guest: Christian Hogg, CEO and Executive Director, Chi-Med
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership talks to Christian Hogg, Executive Director and CEO of Chi-Med, about how the pharmaceutical and biotech industry in China has shifted its priorities from generic medicines to more innovative therapies. Christian talks in depth around the driving factors and investment in innovation, including a reform of the regulatory environment and the vast expansion of access to patients. He also gives his take on why he believes some multi-national companies prosper, and why some fail, when trying to enter the Chinese biotech and pharmaceutical markets, and what they can do to make the most of the growing opportunities within this market. They finish by discussing the possibility that one day China will overtake the US to become the biggest pharmaceutical market in the world. Watch the full episode to find out more.
About our Guest
Christian Hogg, CEO and Executive Director, Chi-Med
Christian joined Chi-Med in 2000, as its first employee, and has since led all aspects of the creation, implementation and management of the company’s strategy, business and listings. This includes the establishment of its Innovation Platform, Hutchison MediPharma, which now comprises eight drug candidates that are being investigated in clinical studies around the world and a scientific team of over 490 people. Furthermore, Christian oversaw the acquisition and operational integration of assets that led to the formation of Chi-Med’s Commercial Platform, which manufactures, markets and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.
About our Host
Mike Ward, Head of Thought Leadership, DRG
Mike Ward serves as Global Head of Thought Leadership at Decision Resources Group (DRG), part of Clarivate. As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership roles at various publications and organizations across the industry.